Holotype HLA™

Ready to implement NGS? Interested in NGS data analysis?

The Holotype HLA Assay is licensed from The Children’s Hospital of Philadelphia (CHOP) and provides amplification and library preparation reagents for comprehensive gene coverage up to 11 HLA loci.

The Software, Omixon HLA Twin, features two independent algorithms for double validation by data analysis to deliver the most accurate, high-resolution genotyping available, with no reflexive testing required.

Believe the data

  • 110+ HLA labs trained onsite worldwide
  • 50+ HLA labs in clinical routine worldwide
  • 20+ customers using CE-IVD products in Europe
  • 12 labs ASHI or CAP accredited in North America
  • 6 labs EFI accredited in Europe
  • 253 samples in ASHI validation study at CHOP

Competitive Advantage - Gene Coverage up to 11 HLA Loci

Holotype HLA provides deep and even coverage of the whole region, with balance between alleles at the same locus, between the loci within a sample and also between samples – up to 96 samples per Miseq run at 11 loci, up to 192 samples at 7 loci and 288 samples at 5 loci - enabling better phasing, reduced ambiguity, and optimal utilization of sequence output.

Coverage plots

Deep and even coverage of two HLA-C alleles assembled simultaneously by the Consensus Genotyping (CG) algorithm in HLA Twin and displayed in the Genome Browser.

Amplification Strategy

The location of the primers provides comprehensive coverage of up to 11 HLA loci with no clinically relevant ambiguities remaining.

Performance Evaluation Study

Click on the table to enlarge.

* Cause by a known limitation of DRB4
** Caused by phasing ambiguity due to a long homozyguous intronic region in DPB1 and by the lack of exon 1 coverage in DRB1

Performance Evaluation Study statistics based on 200 samples, 3 manufacturing lots. Contact Omixon for more detailed product performance information

All Omixon products are available as RUO and certain configurations of Holotype HLA are available as CE-IVD in Europe where marked.